Loading
A phase 3 trial testing SHR-1501 in bladder & urothelial cancer, now recruiting.
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC is a phase 3 interventional study registered as NCT07726992, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Multicenter, Randomised, Double-blind Phase III Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Placebo Combined With BCG In Patients With High-risk BCG-naive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC). Planned enrolment is 750 participants (estimated). The study started in 2026-08-25 and primary completion is expected in 2029-12. No results have been posted on ClinicalTrials.gov.
Shares SHR-1501, Non-muscle-invasive bladder cancer, Jiangsu Hengrui Pharmaceuticals, Bladder & urothelial cancer.
Shares SHR-1501, Jiangsu Hengrui Pharmaceuticals.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.